Herbalife 3rd Quarter 2026 Earnings Conference Call - HERBALIFE LTD

Financial Performance:

• Third quarter net sales reached $1.4 billion, representing a 6% year-over-year (YoY) increase on a reported basis and 7.6% on a constant currency basis, exceeding guidance ranges.
• Adjusted EBITDA was $182 million, up from previous expectations, with an adjusted EBITDA margin of 13.5%, an improvement of 70 basis points YoY.
• Reported net income attributable to Herbalife was $59 million (up 36% YoY); adjusted net income was approximately $69 million.
• Diluted EPS was $0.55 (up $0.13 YoY); adjusted diluted EPS was $0.64 (up $0.14 YoY).
• Gross profit margin stood at 77.3%, down 40 basis points YoY due to country mix, self-manufacturing costs, and other costs, partially offset by pricing benefits.
• Year-to-date operating cash flow totaled $298 million, a 27% increase versus the prior year period.
• Net leverage ratio improved to 2.0 times at quarter end, down from 2.2 times in the second quarter.
• Credit agreement EBITDA was $199 million; net interest expense decreased by $19 million YoY following debt refinancing.
• India drove significant growth, with net sales increasing 39% YoY and nearly 50% in volume.

Guidance and Future Outlook:

• Q4 2026 reported net sales guidance raised to 0.5% to 4.5% YoY (expecting a 200 basis point FX headwind); constant currency sales expected to grow 2.5% to 6.5%.
• Q4 2026 adjusted EBITDA guidance set at $145–$165 million (reported) and $155–$175 million (constant currency), reflecting lower margins relative to Q3.
• Full-year 2026 reported net sales guidance raised to 4.9% to 5.9% YoY; constant currency sales guidance raised to 5.3% to 6.3%.
• Full-year 2026 adjusted EBITDA guidance maintained at $670–$690 million (reported) but raised to $700–$720 million (constant currency).
• Full-year 2026 capital expenditures narrowed to $55–$65 million; capitalized/prepaid SaaS implementation costs narrowed to $35–$45 million.
• Management targets a three-year plan to capture at least 50% of global distributor consumer transactions within their technology ecosystem.
• New technology capabilities are targeted for launch in Q1 2027, starting with the "24 Games" program.

Business Segments and Product Lines:

• Nutrition clubs account for 42% of U.S. volume, with productivity up over 10% YoY and customer foot traffic increasing more than 7%.
• A dedicated internal "nutrition club vertical" is being established to provide tailored tools, products, and training for club-specific business models.
• Bionic brand is being expanded from personalized nutrition into a premium health/wellness brand spanning sports performance and healthy lifespan; it will absorb the Life.io and sports products.
• Protocol is currently in beta with low usage; the company is pivoting to a broader, modular customer engagement platform that allows distributors to customize tools for specific business models (e.g., 24 Games, transformation challenges).
• Product development includes creating specific offerings for consumers using GLP-1 medications and expanding into new consumer segments.
• Global distribution network includes over 64,000 nutrition clubs across 90+ markets with 3+ million entrepreneurs.

Market and Competitive Landscape:

• India remains a primary growth engine, benefiting from GST changes and strong volume growth, though momentum is expected to normalize in Q4.
• Latin America grew 5.1% in constant currency; North America grew 1.7% YoY, driven by revenue recognition timing shifts from Q1.
• EMEA and China faced declines, contributing to the overall country mix headwind.
• Management highlights "human connection" and community-based experiences (e.g., 24 Games) as key differentiators against pure digital competitors, addressing rising global social isolation.
• The 24 Games, a team-based fitness event, held its first U.S. event in Miami with 350+ attendees, serving as a scalable model for global rollout.

Risks and Challenges:

• Foreign exchange rates remain a significant headwind, with a 160 basis point impact in Q3 and an expected 200 basis point headwind in Q4.
• Gross margin pressure persists due to input cost inflation, country mix shifts, and higher other costs, despite pricing actions.
• Regulatory and tax changes, such as the GST impact in India, create variable growth trajectories that must be monitored.
• Execution risk regarding the technology platform transition and the integration of Protocol, Bionic, and Life.io into a cohesive ecosystem.
• Potential slowdown in India growth as the full impact of the prior year's GST change is lapped in Q4.

Management Commentary and Tone:

• New Interim CEO John DeSimone expressed strong confidence in the company's "entrepreneurial spirit" and the platform's ability to enable diverse distributor business models.
• Tone was optimistic yet pragmatic, emphasizing execution on core priorities rather than reinventing the business model.
• Management stressed that "Herbalife succeeds when our distributors succeed," focusing on giving distributors flexibility to adapt programs to local needs.
• Scott Schaefer (CFO) emphasized a disciplined approach to capital allocation and margin expansion, noting that future margin growth will be gradual.
• The leadership team acknowledged the need to improve productivity and accelerate growth despite the strong Q3 performance.

Analyst Questions and Answers:

• GLP-1 Medications: Management confirmed they view GLP-1s as an opportunity, not a threat, and are positioning existing products to coexist with these medications through educational programs rather than new product development.
• Brand Strategy (Bionic, Protocol, Life.io): Bionic is the priority to reach new demographics; Life.io will be rolled into the Bionic brand. Protocol will continue on a parallel track as part of a modular platform, with usage determining its long-term value.
• Technology Platform: The company is moving away from a single app to a common modular foundation that supports various distributor business models (DMOs), starting with the 24 Games in Q1 2027.
• Growth Drivers: India's outperformance was highlighted as a key driver, though management expects continued growth as the GST impact is normalized.

Other Key Points:

• Stefan (previous CEO) was acknowledged for his leadership contributions and distributor background.
• A $250 million share repurchase program was authorized, with plans to commence repurchases in Q4 2026.
• The company ended the quarter with $409 million in cash and paid down $88 million in debt.
• The "24 Games" concept originated from a distributor idea and is being scaled to leverage the unique strength of community-based fitness events.
• Management plans to introduce more convenient formats and premium offerings for Bionic throughout 2027.